GYRE has been in the news 313% more than usual
Jan 06, 2026, 3:32 PM
8.43%
What does GYRE do
Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
GYRE has been in the news recently: GYRE THERAPEUTICS is not mentioned in the article; however, IDEAYA Biosciences and Neurocrine Biosciences, Inc. will both present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. Additionally, BridGene Biosciences has appointed Nobel laureate Bruce A. Beutler to its Scientific Advisory Board to enhance the development of small-molecule therapeutics.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.